177 Lu-DOTATATE Therapy in a Case of Castrate-Resistant Prostate Cancer With Neuroendocrine Differentiation

Qiaoqiao Shu; Xianjun Li; Xi Chen; Yue Chen; Liang Cai

doi:10.1097/RLU.0000000000004735

177 Lu-DOTATATE Therapy in a Case of Castrate-Resistant Prostate Cancer With Neuroendocrine Differentiation

Clin Nucl Med. 2023 Aug 1;48(8):e371-e373. doi: 10.1097/RLU.0000000000004735. Epub 2023 Jun 6.

Authors

Qiaoqiao Shu, Xianjun Li¹, Xi Chen, Yue Chen, Liang Cai

Affiliation

¹ Department of Nuclear Medicine, Weifang People's Hospital, Shandong Province, People's Republic of China.

PMID: 37276491
DOI: 10.1097/RLU.0000000000004735

Abstract

An 84-year-old man with prostate cancer with neuroendocrine differentiation underwent PET/CT for staging. 68 Ga-prostate-specific membrane antigen PET/CT did not show significant abnormal tracer accumulation, whereas 18 F-OC ( 18 F-AlF-NOTA-octreotide) PET/CT showed elevated tracer uptake at multiple sites throughout the body. Therefore, the patient opted to receive 1 cycle of 177 Lu-DOTATATE peptide receptor radionuclide therapy with a dose of 200 mCi. Encouragingly, radiographic tumor remission and improvement of clinical symptoms were observed after only 1 cycle of treatment.

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Humans
Male
Neuroendocrine Tumors* / diagnostic imaging
Neuroendocrine Tumors* / radiotherapy
Octreotide / therapeutic use
Organometallic Compounds* / therapeutic use
Positron Emission Tomography Computed Tomography
Positron-Emission Tomography
Prostatic Neoplasms* / diagnostic imaging
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms* / radiotherapy

Substances

copper dotatate CU-64
Octreotide
Organometallic Compounds